Copanlisib clinical trials
Also written BAY 80-6946 and Aliqopa.
Includes 9 studies of Copanlisib hydrochloride.
How each study uses copanlisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 14 Sept 2017 · ALIQOPA · NDA 209936 (FDA, Drugs@FDA; as copanlisib hydrochloride)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
67 studies that test it; most in 2018 (11)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 11 |
| 2021 | 6 |
| 2022 | 5 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 49
Bayer (18) · National Cancer Institute (NCI) (16) · Memorial Sloan Kettering Cancer Center (4) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Cancer Trials Ireland (2) · Columbia University (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Nivolumab (7) · Rituximab (5) · Venetoclax (3) · Ibrutinib (3) · Gemcitabine (2) · Fulvestrant (2) · Adavosertib (1) · Afatinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test copanlisib.
- Jan 2027A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerPhase 1/2 · Brown University
- Feb 2027Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaPhase 1/2 · City of Hope Medical Center
- Aug 2027Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaPhase 1 · National Cancer Institute (NCI)
- Oct 2027Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaPhase 1 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses copanlisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 67
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04345913Written as Copanlisib Hydrochloride
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03939897Written as Copanlisib Hydrochloride
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04317105Written as Copanlisib Hydrochloride
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03502733Written as Copanlisib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Copanlisib
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400238Written as Copanlisib
- Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT05490771Written as Copanlisib Hydrochloride
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingPhase 1City of Hope Medical CenterNCT03884998Written as Copanlisib
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06360588Written as Copanlisib
- Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03842228Written as Copanlisib Hydrochloride
- Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCLCompletedPhase 2University Hospital MuensterNCT04263584Written as Copanlisib
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT03586661Written as Copanlisib
- Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingPhase 2Christian BuskeNCT03474744Written as Copanlisib
- Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingPhase 1/2City of Hope Medical CenterNCT04939272Written as Copanlisib Hydrochloride
- Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)CompletedPhase 1Cancer Trials IrelandNCT02705859Written as Copanlisib
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03789240Written as Copanlisib
- Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)CompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03581942Written as Copanlisib
- Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedPhase 2M.D. Anderson Cancer CenterNCT05082025Written as Copanlisib
- Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT04572763Written as Copanlisib
- Lung Cancer With Copanlisib and DurvalumabCompletedPhase 1Zhonglin HaoNCT04895579Written as Copanlisib
See all 67 studies that test copanlisib →
Given beside what is tested · 4 — copanlisib is usual care or a partner of the new treatment
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Copanlisib
- Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsCompletedPhase 1BayerNCT03517956Written as Copanlisib (BAY80-6946)
- BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05010096Written as Copanlisib
- Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced CancerCompletedPhase 1BayerNCT01460537Written as BAY80-6946
What changed recently
From the registry's own updates since Oct 20, 2026.
Codes
What other systems call copanlisib · ClinicalTrials.gg INT000019
- MeSH (NLM) C000589253copanlisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WI6V529FZ9COPANLISIBConfirmed FDA, NLM, Wikidata
- RxNorm 1945077One source FDA
- Wikidata Q19903876copanlisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96796CopanlisibOne source FDA
- DrugBank DB12483One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589253 | copanlisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WI6V529FZ9 | COPANLISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1945077 | — | One source FDA |
| Wikidata | Q19903876 | copanlisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96796 | Copanlisib | One source FDA |
| DrugBank | DB12483 | — | One source Wikidata |
Also registered as copanlisib hydrochloride hydrate (UNII W421JK3CPA).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.